Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial


GARON E. B. , CİULEANU T., ARRİETA O., PRABHASH K., SYRIGOS K. N. , GÖKSEL T. , ...Daha Fazla

LANCET, cilt.384, ss.665-673, 2014 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 384 Konu: 9944
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/s0140-6736(14)60845-x
  • Dergi Adı: LANCET
  • Sayfa Sayıları: ss.665-673

Özet

Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy.